Published
January 26, 2026
Updated
July 27, 2026
The $264 million EpiPen settlement resolved claims that consumers and health plans overpaid for the epinephrine auto-injector. Claims closed years ago, but the administrator opened a second distribution to already-approved claimants in March 2026 — this page explains what that means and what it does not.
Current Status
Claims are closed and no new claims are accepted. Payments in the $264 million EpiPen settlement began in 2023, and the settlement administrator commenced a second distribution on March 26, 2026 to claimants with an approved claim and a payment of at least $5.00. Eligible claimants were notified by email at the address on their claim form. A further payment is not guaranteed for every claimant, and OpenClassActions.com is not the settlement administrator — the only reliable confirmation is what you receive through the official settlement payment process.StatusPayments in Progress — Second DistributionSecond distribution commenced March 26, 2026.
Claim DeadlinePassedThe settlement is closed to new claims.
Settlement Fund$264,000,000Some claimants previously reported first-round payouts above $1,500.
Proof RequiredNot applicableNothing to file — the distribution goes to claims already approved.
What Is the Second Distribution?
Large class action settlements often produce more than one payment round. Money can remain in a fund after the first distribution because of claim corrections, returned or uncashed checks, failed electronic payments, or other administrative adjustments, and the administrator then redistributes what is left to approved claimants. That is the general mechanism behind the additional EpiPen payments claimants began reporting in early 2026.According to the administrator, the second distribution began on March 26, 2026 and went to consumers with a valid claim whose share met a minimum of $5.00. Those claimants were sent an email at the address provided on their claim form. If you previously received an EpiPen settlement payment, the safest assumption is that you should not expect another one unless you receive an official notice tied to your claim.
What Was the Case About?
The litigation involved allegations that certain EpiPen products were priced or marketed in a way that harmed competition and caused consumers and third-party payors to overpay. The defendants denied wrongdoing and agreed to a $264 million settlement fund to avoid the cost and risk of continued litigation. The case was handled in the U.S. District Court for the District of Kansas as part of the EpiPen multidistrict litigation.A separate $123.5 million direct purchaser settlement covered wholesalers, pharmacies and institutions that bought EpiPen straight from the manufacturer.
Who Qualified Originally?
The settlement generally defined qualifying class members as people or entities in the United States who paid for, or provided reimbursement for, some or all of the purchase price of certain EpiPen products for consumption rather than resale during the class period. Some states were treated differently for certain categories, and the settlement website and official notices controlled those definitions.How Were Payments Issued?
Based on the settlement's payment instructions and claimant reports, payments were distributed through a digital payment portal offering options such as PayPal, Venmo, direct deposit or a virtual prepaid card, with mailed checks used for some claimants depending on the method selected. Additional payments generally use the method a claimant previously chose, though administrator procedures can vary. Digital payments typically carry a redemption deadline, so claimants who received an email notification should act on it rather than assume the payment will wait indefinitely.Do Claimants Need to Do Anything?
In most settlements, additional distributions are processed automatically for approved claimants. If you receive an email asking you to choose a payment method again, confirm it is genuinely connected to the official settlement website before entering any information. Monitor the same email address you used on your claim form.Watch for Settlement Scams
Settlement-related scams are common whenever a payment round makes the news. Be cautious of any message that asks for your Social Security number to "release" a payment, demands a fee before you can receive settlement money, threatens penalties if you do not respond immediately, or uses a look-alike domain or a misspelled sender address. When in doubt, close the email, type the official settlement website address into your browser directly, and use the contact form there.What Happens Next?
The administrator controls the timing and scope of any remaining distribution. No additional payment round beyond the March 2026 distribution had been announced as of July 27, 2026. Updates are posted on the official settlement website.Official information is available at EpiPen Class Action.
Sources
• Official settlement website: EpiPen Class Action• Settlement notice and distribution updates posted by the settlement administrator
• In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation, U.S. District Court for the District of Kansas
For more class actions keep scrolling below.
Settlement Fund
$264,000,000
Case Title
In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation
Court
U.S. District Court for the District of Kansas
Category
Consumer Overcharge / Antitrust
Claim Deadline
Passed — closed to new claims
Status
Payments in Progress — second distribution began March 26, 2026
Official Website
EpiPen Class Action
